Ci3 e.V.

Ci3 e.V.

Ci3 e.V.

The non-profit organization Ci3 e.V., which was financed by state funds till 2012 and then with membership dues, is the central interface between the cluster’s various bodies and institutions. The private and institutional club members from business, medicine and academia are represented by the volunteer board members PD Dr. Özlem Türeci and Prof. Dr. Christoph Huber.

CI3 e.V.

PD Dr. Özlem Türeci
1. Chairman Ci3 e.V.

Özlem Türeci has dedicated more than two decades to the discovery of unique drug targets with exceptional cancer-cell selectivity and to the creation of potent immunotherapy drug platforms to enable treatment of patients in an individualized and tailored manner. This is documented by the filing of more than 530 international patent applications and granted patents, and by the publication of more than 75 articles in peer-reviewed scientific journals. She is co-founder and CEO of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing unique high-precision antibodies against various solid cancers. Furthermore, Özlem Türeci is an executive board member of the Association for Cancer Immunotherapy e.V. (CIMT). She was awarded the Vincenz Czerny Prize of the German Association for Hematology and Oncology and various other prizes and scholarships for her work.

Prof. Dr. Christoph Huber
2. Chairman Ci3 e.V.

Christoph Huber is professor emeritus and former Head of the department of Hematology and Oncology at the Johannes Gutenberg University Medical School in Mainz, Germany. Past and present personal research interests are tumor immunology (molecular characterization of tumor-associated antigens, therapeutic T-cell receptor transfer, tumor immune escape mechanisms) and transplantation biology (mechanisms of graft-versus-host disease and their therapeutic manipulation, characterization of minor histocompatibility antigens, T cell repertoire shaping by activation-induced-cell-death). Professor Huber has held many national and international appointments in various research organizations and regulatory agencies. He is also chairman of the Association for Cancer Immunotherapy (CIMT) and Senior advisor to international pharmaceutical companies and big science institutions.